Rockefeller University's Center for Clinical and Translational Science funds pilot studies

January 07, 2008

The Rockefeller University Center for Clinical and Translational Science (CCTS) has announced the recipients of its 2008 Pilot Project grants. Eight Rockefeller researchers will each receive $25,000 from the center to fund early studies in translational science that, if successful, might lead to clinical trials. The CCTS and the grant program are in their second year, established through funds from a Clinical and Translational Science Award the university received from the National Center for Research Resources of the National Institutes of Health. In its first year, the program provided $165,000 for nine clinical studies.

The center's administration selected the 2008 pilot projects from among proposals submitted in the fall. The recipients are:
-end-
Rockefeller University has a long history of clinical and translational research. The Rockefeller University Hospital, built in 1910 as an integral part of the Rockefeller Institute for Medical Research (the university's original name), was the birthplace of American biomedical and translational science, being the first hospital in the United States devoted primarily to medical research. Many scientific discoveries made at Rockefeller have had a dramatic impact on medicine, including the landmark 1944 discovery by Oswald Avery, Colin MacLeod and Maclyn McCarty that DNA is the chemical substance of heredity, which grew out of studies of patients with pneumococcal pneumonia; the development of methadone treatment to manage heroin addiction by Vincent Dole, Marie Nyswander and Mary Jeanne Kreek; and the development of multiple drug regimens to treat HIV/AIDS, based on human studies of the dynamics of viral replication by David Ho and his colleagues.

Rockefeller University

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.